Search

Displaying results 11 - 13 of 13 in total
  1. Drug

    Omfiloctocog alfa

    go.drugbank.com/drugs/DB19229
    Investigational

    Omfiloctocog alfa is under investigation in clinical trial NCT03947567 (Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia a Patients.).

    Synonyms: FACTOR VIII (RECOMBINANT HUMAN SCT800 LIGHT, HUMAN COAGULATION FACTOR VIII (FVIII, ANTIHEMOPHILIC FACTOR, AHF, PROCOAGULANT COMPONENT) WITH DELETED B-DOMAIN (746-1639)-SEQUENCE: SINGLE-CHAIN RECOMBINANT FVIII COMPOSED OF DOMAINS A1-A1-A2-A2 (1-740
  2. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    Simoctocog alfa is a recombinant B-domain deleted (BDD) rFVIII produced in genetically modified human embryonic kidney (HEK) 293F cells. … Full human post-translational modifications via elimination of potentially immunogenic glycosylation patterns found in non-human cell lines led to decreased immunogenicity and longer half-life [A31525]

  3. Drug

    Damoctocog alfa pegol

    go.drugbank.com/drugs/DB14700
    ApprovedInvestigational

    In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval. … [A38907] Also known as, BAY94-9027, Damoctocog alfa pegol is a longer-acting Factor VIII therapy formulated with polyethylene glycol (PEG) to reduce the number of infusions necessary to prevent bleeds

    Categories: Blood Coagulation Factors